Pneumococcal conjugate second or third-dose vaccines (PCVc) in Azerbaijan
Azerbaijan: Pneumococcal conjugate second or third-dose vaccines (PCVc) was 52.0% in 2025. ◆ Volatile
Latest (2025)
52.0%
Change on year
unchanged
World rank
155th
of 194 countries
All-time high
79.0%
in 2015
All-time low
0.0%
in 2008
Years of data
18
2008–2025
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Azerbaijan, 2008–2025
Source: World Health Organization, Global Health Observatory.
Analysis
Azerbaijan recorded 52.0% for pneumococcal conjugate second or third-dose vaccines (pcvc) in 2025.
Compared with earlier readings it is down 34.2% over ten years.
Over the whole period, pneumococcal conjugate second or third-dose vaccines (pcvc) in Azerbaijan peaked at 79.0% in 2015 and was at its lowest, 0.0%, in 2008.
Azerbaijan ranks 155th of 194 countries on this measure, in the bottom quarter.
The series is highly variable year to year, so single readings are best treated with caution.
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Azerbaijan, year by year
| Year | Value | Change |
|---|---|---|
| 2008 | 0.0% | — |
| 2009 | 0.0% | — |
| 2010 | 0.0% | — |
| 2011 | 0.0% | — |
| 2012 | 0.0% | — |
| 2013 | 0.0% | — |
| 2014 | 52.0% | — |
| 2015 | 79.0% | +51.9% |
| 2016 | 79.0% | +0.0% |
| 2017 | 74.0% | -6.3% |
| 2018 | 70.0% | -5.4% |
| 2019 | 66.0% | -5.7% |
| 2020 | 47.0% | -28.8% |
| 2021 | 50.0% | +6.4% |
| 2022 | 52.0% | +4.0% |
| 2023 | 52.0% | +0.0% |
| 2024 | 52.0% | +0.0% |
| 2025 | 52.0% | +0.0% |
Azerbaijan compared with similar countries
- Azerbaijan's 52.0% is below the median for upper middle income countries, which is 76.0%, 68% of the median. (57 countries reporting)
- Azerbaijan's 52.0% is below the median for Europe & Central Asia, which is 87.0%, 60% of the median. (51 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | 2 |
| 2010s | 42.0% | 0.0% | 79.0% | 10 |
| 2020s | 50.8% | 47.0% | 52.0% | 6 |
Countries ranked near Azerbaijan
More health data for Azerbaijan
- Un projection of annual infant deaths, annual growth rate -1.12 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate -0.1127 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,241 deaths per 1,000 people (2090)
- Number of infants who die before age 1 264 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2025)
- Population ages 00-04, female, annual growth rate -3.72 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0286 units per person (2025)
- Population ages 00-04, male, annual growth rate -4.06 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is pneumococcal conjugate second or third-dose vaccines (pcvc) in Azerbaijan?
- Pneumococcal conjugate second or third-dose vaccines (pcvc) in Azerbaijan was 52.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Azerbaijan?
- The highest recorded value was 79.0% in 2015.
- What is the lowest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Azerbaijan?
- The lowest recorded value was 0.0% in 2008.
- How does Azerbaijan rank for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Azerbaijan ranks 155th out of 194 countries with data for 2025.
- Is pneumococcal conjugate second or third-dose vaccines (pcvc) rising or falling in Azerbaijan?
- Over the last ten years it is down 34.2%. The long-run trend across the full record is volatile.
- Where does this Azerbaijan data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 18 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).